http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
Rowan E Miller,Karim H El-Shakankery,이정윤 대한부인종양학회 2022 Journal of Gynecologic Oncology Vol.33 No.3
The use of PARP inhibitors (PARPi) in patients with epithelial ovarian cancer is expanding,with the transition from use in recurrent disease to the first-line setting. This is accompaniedwith an increasing population of patients who develop acquired PARPi resistance. Coupledwith those patients with primary PARPi resistance, there is an urgent need to better understand mechanisms of resistance and identify means to overcome this resistance. Combination therapy offers the potential to overcome innate and acquired resistance, by either working synergistically with PARPi or by restoring homologous recombination deficiency, targeting the homologous recombination repair pathway through an alternate strategy. We discuss mechanisms of PARPi resistance and data on novel combinations which may restore PARPi sensitivity.